SMI microarray technical details.
Multi-viral: Includes S and N proteins from SARS-CoV-2, SARS-CoV, MERS-CoV and influenza. Proteins are purified and printed in triplicate. Each microarray contains 14 identical sub-arrays produced by contact printing.
Multiplexed: Simultaneously detect serum IgG/IgM and profile the immune responses against several viral proteins.
Accurate: Direct comparison of proteins from SARS-CoV-2, SARS-CoV, and MERS-CoV is possible for each patient sample on a single array; false negatives or non-specific binding can be evaluated. The combination of multiple markers on each array also contributes to the specificity and accuracy of the readout.
Flexible: As new SARS-CoV-2 mutations are discovered in clinical samples, CDI can add these mutated proteins directly onto the SMI Protein Array to provide a deeper look into how these new mutations impact disease. For clinical applications, the SMI Protein Array is a flexible platform for discovering and then combining different markers to help advance disease diagnosis, prognosis and classify disease severity.
Sensitive: Using only 1 microliter of serum for the assay (less than a drop of blood) considerable data can be acquired and subjected to bioinformatic analysis for research, clinical, and epidemical use.
Specific: The SMI Protein Array will accelerate the development of highly specific biological products for disease detection and other medical uses.